StreetAlpha.app
Home › Stocks › PACB

Pacific Biosciences of California, Inc. (PACB)

Healthcare
$1.63
▼ −7.39%
LAST CLOSE · NOV 20

Pacific Biosciences makes DNA sequencing systems, reagents and services for researchers, clinical labs and drug developers. It last closed at $1.63 on Nov 20, down 7.39% on the day. The next earnings report for PACB is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, PACB reported EPS of -$0.12 on revenue of $40.6M, with revenue up 5.5% from a year ago. Over its last 8 reports the stock moved an average of 9.4% the session after earnings. Over the last 12 months PACB insiders bought $0 of stock on the open market and sold $3.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is PACB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PACB.

Key Stats

Last 12 months
Results
Revenue
$161.4M
+4.4% vs a year ago
Net income
−$131.2M
−81.3% margin
EPS (diluted)
−$0.42
Free cash flow
−$143.4M
−88.8% margin
Valuation
Market cap
$510.1M
312.9M shares
P/E
–
No P/E while losing money
Price to sales
3.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.9M
At Sep 30
Debt
$643.1M
At Sep 30
Shareholder equity
−$61.4M
Shares outstanding
312.9M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $130.5M$130.5MFY2021FY2022: $128.3M$128.3MFY2022FY2023: $200.5M$200.5MFY2023FY2024: $154.0M$154.0MFY2024FY2025: $160.0M$160.0MFY2025

From PACB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.12
Quarter ended Sep 2026
Year ago EPS
-$0.13
Same quarter last year
Revenue
$40.6M
+5.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.44Dec '24Mar 2025: -$1.44Mar '25Jun 2025: -$0.14Jun '25Sep 2025: -$0.13Sep '25Dec 2025: -$0.13Dec '25Mar 2026: -$0.03Mar '26Jun 2026: -$0.14Jun '26Sep 2026: -$0.12Sep '26Latest -$0.12
Revenue by quarter
Dec 2024: $39.2MDec '24Mar 2025: $37.2MMar '25Jun 2025: $39.8MJun '25Sep 2025: $38.4MSep '25Dec 2025: $44.6MDec '25Mar 2026: $37.2MMar '26Jun 2026: $39.0MJun '26Sep 2026: $40.6MSep '26Latest $40.6M
How PACB moved after its last 8 reports
Average move the session after a report ±9.4%
Nov 4, 2026After the close−4.7%
Aug 5, 2026After the close−10.4%
May 7, 2026After the close−14.6%
Feb 12, 2026After the close−7.1%
Jan 12, 2026Time not announced+3.6%
Nov 5, 2025After the close−7.0%
Aug 7, 2025After the close+7.1%
Apr 9, 2025Time not announced+20.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PACBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PACB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PACB

Technical Analysis

PACB · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 37% below its 20 day and 26% below its 50 day average. It is 2% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 35), near oversold. The nearest support is the 200 day average at $1.60, and the nearest resistance the Pivot at $1.66.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 15.1%/day
Key levels
$3.4452 week high+111.0%
$2.2320 day average+36.8%
$2.0550 day average+25.8%
$1.77Swing high (Jun 4)+8.6%
$1.71100 day average+4.9%
$1.70Pivot R1+4.3%
$1.66Pivot+1.8%
$1.63Last close
$1.60200 day average−1.8%
$1.58Pivot S1−3.1%
$1.32Swing low (Jul 24)−19.0%
$1.0752 week low−34.4%
Indicators
RSI (14)35.29Weak, oversold below 30Neutral
MACD-0.11Below its signal lineBearish
Stochastic5.3Near the bottom of its rangeOversold
ADX (14)23.1Weak trend
Williams %R-98.2Oversold below −80, overbought above −20Oversold
CCI (20)-134.6Oversold below −100, overbought above 100Oversold
Rate of change−27.7%Change over 10 sessionsBearish
ATR (14)$0.25Typical daily range, 15.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for PACB

What happened before

See how PACB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PACB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PACB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PACBHow many large options trades hit PACB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

PACB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●90 buying vs 98 selling
  • ▲Held by funds +7.3 pts
  • ▼Funds holding -18
  • ▼Superinvestors: 2 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding205223−8.1%
In funds' top 10110.0%
Held by funds68.4%61.1%+7.3 pts
New / increased23 / 6723 / 70−3.2%
Reduced / sold out58 / 4077 / 29−7.5%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PACB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PACB Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$3.4M10 sales · 5 insiders
60% of the selling was under pre-arranged trading plans.
2026-02 sold $1.1M2026-03 sold $33K2026-04 sold $121K2026-08 sold $30K2026-10 sold $2.1M2026-11 sold $33KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Kathy OrdonezDirectorSale18,595$1.78$33K
Oct 6James R Gibson IISee RemarksSale plan661,815$3.11$2.1M
Aug 17Oene Mark VanSee RemarksSale26,911$1.13$30K
Apr 1James R Gibson IISee RemarksSale88,185$1.37$121K
Mar 3Michele FarmerSee RemarksSale2,979$1.51$4K
Mar 3Oene Mark VanSee RemarksSale6,504$1.51$10K
Every insider buy and sale for PACB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PACB insider trades →

From SEC Form 4 filings by PACB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PACB is in one of them and how their past PACB trades turned out.

PACB in the AI portfolios
Loading…

PACB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PACB in an article yet. Here's the latest on the wider market.

PACB in the news

About Pacific Biosciences of California

Pacific Biosciences is a life science technology company based in Menlo Park, California, that designs and makes DNA sequencing systems. Its offerings include sequencing instruments, nanofluidic chips, reagents, software and sequencing services that read long stretches of DNA with high accuracy. Its customers include academic and government research institutions, clinical and testing laboratories, hospitals, public health labs, pharmaceutical companies, contract research organizations and agricultural companies.

Headquarters
Menlo Park, CA
Founded
2004